Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by talisman47on Oct 29, 2020 2:48pm
139 Views
Post# 31804830

RE:Opportunity ?

RE:Opportunity ?I think yesterday was Chris  being very low key providiing a general update of things. I felt he was stumbling around a bit explaining or justifying why they aren't announcing 150 enrolled yet. His explanation gave me the impression they may have the last 37 enrolled but he says that the doctors and data entry people are extremely busy and until they have all the entry enrollment data for those up to 150 he doesn't wnat to say full enrollment yet.. Also, it may  get  them to the  two week data on the 150 before officially announcing full enrollment. Seems like they are buying a little time right now for some reason.

This is also month end, maybe they are trying to reduce short sellers, maybe they don't want to announce anything until after US election on Tuesday as it is a big distraction, etc.

Looking forward  to positive news in November.
<< Previous
Bullboard Posts
Next >>